DYNLT4

Summary

DYNLT4 (dynein light chain Tctex-type 4, HGNC:32315) is a protein-coding gene on chromosome 1p34.1, encoding Dynein light chain Tctex-type 4 (Q5JR98).

Enables protein phosphatase 1 binding activity. Predicted to be involved in microtubule-based movement. Located in acrosomal vesicle; cytoskeleton; and sperm flagellum.

Source: NCBI Gene 343521 — automated summary from GO annotations (Alliance of Genome Resources).

At a glance

• Clinical variants (ClinVar): 61 total
• GTEx eGene: eQTL in 15 tissues, sQTL in 0 (q < 0.05)
• Constraint (gnomAD): pLI 0.00 (LoF-tolerant), LOEUF 1.94 (unconstrained)
• MANE Select transcript: NM_001377534
• Notable: 61 clinical variants but no curated precision-oncology (CIViC) evidence yet

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:32315
Approved symbol	DYNLT4
Name	dynein light chain Tctex-type 4
Location	1p34.1
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000188396
Ensembl biotype	protein_coding
OMIM	611713
Entrez	343521

Gene structure

Transcript identifiers

Ensembl transcripts: 12 — 12 protein_coding

MANE Select: ENST00000339355

ENST00000339355, ENST00000675259, ENST00000854447, ENST00000854448, ENST00000854449, ENST00000854450, ENST00000854451, ENST00000854452, ENST00000854453, ENST00000942935, ENST00000942936, ENST00001145719

RefSeq mRNA: 4 — MANE Select: NM_001377534 NM_001013632, NM_001377534, NM_001377535, NM_001377536

CCDS: CCDS30699

Canonical transcript exons

ENST00000339355 — 3 exons

Exon	Start	End
ENSE00001369237	44805893	44806679
ENSE00003899086	44807325	44807351
ENSE00003903990	44806784	44806838

Expression profiles

Bgee: expression breadth ubiquitous, 123 present calls, max score 94.54.

FANTOM5 (CAGE): breadth broad, TPM avg 0.7414 / max 70.9613, expressed in 230 samples.

Highest expression (Bgee): uterine tube, olfactory segment of nasal mucosa, bone marrow cell, fallopian tube, bone marrow.

Genetic regulation across tissues (GTEx eQTL / sQTL)

DYNLT4 is an eGene in GTEx v10 — its expression is genetically regulated (eQTL) in 15 tissues and its splicing (sQTL) in 0 (q < 0.05). Strongest associations first; slope = normalized effect of the lead variant’s alternative allele.

15 significant tissue × QTL associations:

Tissue	QTL	q-value	Slope	Lead variant
Artery Tibial	eqtl	1.1e-06	-0.31	1:44751388:G:A
Artery Aorta	eqtl	2.0e-04	-0.27	1:44764789:G:A
Skin Sun Exposed Lower leg	eqtl	3.4e-04	-0.24	1:44817885:T:C
Adipose Visceral Omentum	eqtl	4.9e-04	-0.19	1:44826036:G:T
Heart Atrial Appendage	eqtl	9.3e-04	-0.32	1:44817885:T:C
Nerve Tibial	eqtl	1.3e-03	-0.22	1:44821300:C:T
Esophagus Mucosa	eqtl	1.4e-03	-0.19	1:44819674:C:T
Cells Cultured fibroblasts	eqtl	2.0e-03	-0.13	1:44809879:A:C
Whole Blood	eqtl	4.2e-03	+0.24	1:44520523:C:A
Lung	eqtl	5.1e-03	-0.17	1:44811472:C:T
Spleen	eqtl	5.3e-03	-1.12	1:44112730:A:G
Skin Not Sun Exposed Suprapubic	eqtl	7.9e-03	-0.19	1:44809938:TCTC:T
Pituitary	eqtl	2.7e-02	+0.41	1:44102650:A:G
Adipose Subcutaneous	eqtl	3.0e-02	+0.21	1:44416015:GCAT:G
Pancreas	eqtl	3.8e-02	+0.38	1:44423880:A:G

FANTOM5 promoters

2 alternative TSS:

Promoter ID	TPM avg	Samples expressed
12096	0.6943	220
12095	0.0472	18

Top tissues by expression

showing 100 of 127 tissues by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right uterine tube	UBERON:0001302	94.54	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	92.02	gold quality
bone marrow cell	CL:0002092	72.88	gold quality
fallopian tube	UBERON:0003889	71.52	gold quality
bone marrow	UBERON:0002371	68.96	gold quality
blood	UBERON:0000178	68.61	gold quality
stromal cell of endometrium	CL:0002255	68.25	gold quality
mucosa of stomach	UBERON:0001199	67.02	gold quality
right adrenal gland cortex	UBERON:0035827	66.97	gold quality
left uterine tube	UBERON:0001303	66.27	gold quality
left adrenal gland cortex	UBERON:0035825	66.21	gold quality
right lung	UBERON:0002167	66.19	gold quality
left adrenal gland	UBERON:0001234	66.12	gold quality
right adrenal gland	UBERON:0001233	66.07	gold quality
descending thoracic aorta	UBERON:0002345	65.67	gold quality
thoracic aorta	UBERON:0001515	64.72	gold quality
ascending aorta	UBERON:0001496	64.54	gold quality
adrenal gland	UBERON:0002369	63.58	gold quality
gall bladder	UBERON:0002110	63.11	gold quality
apex of heart	UBERON:0002098	62.26	gold quality
monocyte	CL:0000576	61.90	gold quality
upper lobe of left lung	UBERON:0008952	61.06	gold quality
leukocyte	CL:0000738	60.85	gold quality
lung	UBERON:0002048	60.60	gold quality
granulocyte	CL:0000094	60.19	gold quality
omental fat pad	UBERON:0010414	59.51	gold quality
minor salivary gland	UBERON:0001830	59.05	gold quality
smooth muscle tissue	UBERON:0001135	59.00	gold quality
saliva-secreting gland	UBERON:0001044	57.88	gold quality
right coronary artery	UBERON:0001625	57.45	gold quality
hindlimb stylopod muscle	UBERON:0004252	57.43	gold quality
lower esophagus muscularis layer	UBERON:0035833	57.42	gold quality
esophagus	UBERON:0001043	57.37	gold quality
myometrium	UBERON:0001296	57.37	gold quality
lower esophagus	UBERON:0013473	57.30	gold quality
esophagus mucosa	UBERON:0002469	57.12	gold quality
metanephros cortex	UBERON:0010533	57.02	gold quality
body of uterus	UBERON:0009853	56.83	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	56.46	gold quality
heart left ventricle	UBERON:0002084	56.36	gold quality
vermiform appendix	UBERON:0001154	56.34	gold quality
left coronary artery	UBERON:0001626	56.32	gold quality
liver	UBERON:0002107	55.97	gold quality
adenohypophysis	UBERON:0002196	55.53	gold quality
right atrium auricular region	UBERON:0006631	55.23	gold quality
body of stomach	UBERON:0001161	55.07	gold quality
uterine cervix	UBERON:0000002	55.03	gold quality
heart	UBERON:0000948	55.03	gold quality
thyroid gland	UBERON:0002046	54.94	gold quality
muscle tissue	UBERON:0002385	54.66	gold quality
body of pancreas	UBERON:0001150	54.64	gold quality
left lobe of thyroid gland	UBERON:0001120	54.58	gold quality
colonic epithelium	UBERON:0000397	54.52	gold quality
cortex of kidney	UBERON:0001225	54.37	gold quality
pituitary gland	UBERON:0000007	54.31	gold quality
endocervix	UBERON:0000458	54.24	gold quality
adipose tissue	UBERON:0001013	54.18	gold quality
popliteal artery	UBERON:0002250	54.13	gold quality
tibial artery	UBERON:0007610	54.10	gold quality
duodenum	UBERON:0002114	53.48	gold quality
sural nerve	UBERON:0015488	53.42	gold quality
stomach	UBERON:0000945	53.36	gold quality
skin of abdomen	UBERON:0001416	52.72	gold quality
right lobe of thyroid gland	UBERON:0001119	52.63	gold quality
small intestine	UBERON:0002108	52.52	gold quality
ectocervix	UBERON:0012249	52.43	gold quality
small intestine Peyer’s patch	UBERON:0003454	52.07	gold quality
right lobe of liver	UBERON:0001114	51.91	gold quality
skeletal muscle tissue	UBERON:0001134	51.67	gold quality
pancreas	UBERON:0001264	51.66	gold quality
transverse colon	UBERON:0001157	51.43	gold quality
multicellular organism	UBERON:0000468	51.15	gold quality
urinary bladder	UBERON:0001255	51.07	gold quality
ovary	UBERON:0000992	50.85	gold quality
left ovary	UBERON:0002119	50.77	gold quality
zone of skin	UBERON:0000014	50.70	gold quality
thoracic mammary gland	UBERON:0005200	50.59	gold quality
intestine	UBERON:0000160	50.58	gold quality
kidney	UBERON:0002113	50.56	gold quality
rectum	UBERON:0001052	50.48	gold quality
colon	UBERON:0001155	50.41	gold quality
calcaneal tendon	UBERON:0003701	50.28	silver quality
vagina	UBERON:0000996	50.16	gold quality
spleen	UBERON:0002106	50.12	gold quality
adult mammalian kidney	UBERON:0000082	50.01	gold quality
subcutaneous adipose tissue	UBERON:0002190	49.94	gold quality
placenta	UBERON:0001987	49.88	gold quality
adrenal tissue	UBERON:0018303	49.76	gold quality
gastrocnemius	UBERON:0001388	49.60	gold quality
tonsil	UBERON:0002372	49.56	gold quality
muscle of leg	UBERON:0001383	49.50	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	49.50	gold quality
lymph node	UBERON:0000029	49.49	gold quality
right ovary	UBERON:0002118	49.36	gold quality
muscle layer of sigmoid colon	UBERON:0035805	49.32	gold quality
skin of leg	UBERON:0001511	49.06	gold quality
lower esophagus mucosa	UBERON:0035834	48.84	gold quality
endometrium	UBERON:0001295	47.88	gold quality
hypothalamus	UBERON:0001898	46.72	gold quality
prostate gland	UBERON:0002367	45.51	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-CURD-114	yes	60.74
E-ANND-3	yes	9.54

HPA expression

RNA tissue specificity: Group enriched

showing 60 of 72 HPA tissues / cells by nTPM:

Tissue / cell	Axis	nTPM	Protein (IHC)
Choroid plexus	tissue	43.4
Locus coeruleus	tissue	5.2
Periaqueductal gray	tissue	4.1
Fallopian tube	tissue	4.0	high
Nucleus accumbens	tissue	2.7
Hippocampus	tissue	2.3	not detected
Bone marrow	tissue	2.3	not detected
Epididymis	tissue	2.1	not detected
Caudate putamen	tissue	1.9
Gallbladder	tissue	1.7	not detected
Pons	tissue	1.5
Hypothalamus	tissue	1.4
Hippocampal formation	tissue	1.3
Appendix	tissue	1.2	not detected
Septum	tissue	1.1
Stomach 1	tissue	1.0	not detected
Lung	tissue	1.0	not detected
Basal ganglia	tissue	0.9	not detected
Pituitary gland	tissue	0.8
Medulla oblongata	tissue	0.8
Corpus callosum	tissue	0.8
Adrenal gland	tissue	0.8	not detected
Endometrium 1	tissue	0.7	not detected
Spinal cord	tissue	0.7
Esophagus	tissue	0.6	not detected
Midbrain	tissue	0.6
Thalamus	tissue	0.6
Superior colliculi	tissue	0.6
Substantia nigra	tissue	0.6
Thyroid gland	tissue	0.6	not detected
Amygdala	tissue	0.5
Postcentral gyrus	tissue	0.5
Ventral forebrain	tissue	0.5
Cerebral cortex	tissue	0.4	not detected
Motor cortex	tissue	0.4
Cerebellum	tissue	0.4	not detected
Small intestine	tissue	0.4	not detected
Duodenum	tissue	0.4	not detected
Retrosplenial cortex	tissue	0.4
Skin 1	tissue	0.3	not detected
Vagina	tissue	0.3	not detected
Salivary gland	tissue	0.3	not detected
Parathyroid gland	tissue	0.3	not detected
Pancreas	tissue	0.3	not detected
Putamen	tissue	0.3
Liver	tissue	0.3	not detected
Temporal cortex	tissue	0.3
Occipital cortex	tissue	0.3
Insular cortex	tissue	0.3
Lymph node	tissue	0.2	not detected
Breast	tissue	0.2	not detected
Prefrontal cortex	tissue	0.2
Heart muscle	tissue	0.2	not detected
Seminal vesicle	tissue	0.2	not detected
Skeletal muscle	tissue	0.2	not detected
Colon	tissue	0.2	not detected
Spleen	tissue	0.2	not detected
Entorhinal cortex	tissue	0.2
Retrosplenial and cingulate cortex	tissue	0.2
Olfactory bulb	tissue	0.2

Brain sub-regions (HPA Brain Atlas): detected in 191; highest nTPM — Area postrema (12.0), Habenula (10.4), Periaquaductal grey, lateral (9.6), Nucleus tractus solitarii (9.2), Nucleus raphe pallidus (8.9).

Regulation

Is transcription factor: no

Functional genomics

gnomAD constraint: pLI 0.000437, LOEUF 1.94, missense Z -2.04 — population loss-of-function intolerance (pLI ≥ 0.9 = LoF-intolerant; lower LOEUF = more constrained). gnomAD

Regional missense constraint (gnomAD RMC): no regional variation along ENST00000339355 — one region, missense o/e 1.01.

Literature-anchored findings (GeneRIF, showing 1)

• 40 novel TCTEX1D4 interactors in human spermatozoa have been identified. (PMID:24606217)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Dynlt4	ENSMUSG00000047671
rattus_norvegicus	Dynlt4	ENSRNOG00000018463

Paralogs (5): DYNLT1 (ENSG00000146425), DYNLT5 (ENSG00000152760), DYNLT3 (ENSG00000165169), DYNLT2 (ENSG00000184786), DYNLT2B (ENSG00000213123)

Mouse-model phenotypes

Observed phenotypes of the mouse ortholog (MGI:3045358) from MGI (Alliance of Genome Resources) — knockout/mutant phenotypes, ranked by annotation count. 3 distinct phenotype terms.

Mouse phenotype (MP)	Records
decreased hematocrit	1
decreased hemoglobin content	1
decreased erythrocyte cell number	1

Additional cross-species homologs

Sequence homologs in species beyond Ensembl Compara’s model organisms, by Diamond local protein alignment (% sequence identity; best hit per species). Lower-identity rows are more distant homologs. The matched accessions’ gene symbols aren’t in biobtree yet, so each row shows the UniProt accession.

Organism	UniProt	Identity	Method
Xenopus laevis	A2VDD2	96.0%	Diamond
Bos taurus	Q32P71	94.1%	Diamond
Sus scrofa	Q4VYA0	80.1%	Diamond
Danio rerio	Q66IC8	70.5%	Diamond

Genomic neighbors (locus context)

Genes flanking this one on the chromosome (NCBI/Entrez gene neighborhood). Positional context only — some neighbors share regulatory elements (bidirectional promoters, antisense/overlapping transcripts), but chromosomal adjacency is not itself a functional relationship (see Interactions for that).

Symbol	Type	Entrez
PLK3	protein-coding	1263
BTBD19	protein-coding	149478
PTCH2	protein-coding	8643
EIF2B3	protein-coding	8891
BEST4	protein-coding	266675
RPS8	protein-coding	6202
SNORD38A	snoRNA	94162
SNORD38B	snoRNA	94163

Protein

Protein identifiers

Dynein light chain Tctex-type 4 — Q5JR98 (reviewed: Q5JR98)

Alternative names: Protein N22.1, Tctex-2-beta, Tctex1 domain-containing protein 4

All UniProt accessions (1): Q5JR98

UniProt curated annotations — full annotation on UniProt →

Subunit / interactions. Interacts with ENG/endoglin, TGFBR2 and TGFBR3. Interacts with PPP1CC.

Subcellular location. Cell projection. Cilium. Flagellum. Cytoplasmic vesicle. Secretory vesicle. Acrosome. Cytoplasm. Cytoskeleton. Cilium axoneme. Nucleus. Microtubule organizing center.

Tissue specificity. Ubiquitously expressed. Expressed in testis (at protein level).

Similarity. Belongs to the dynein light chain Tctex-type family.

RefSeq proteins (4): NP_001013654, NP_001364463, NP_001364464, NP_001364465 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR005334	Tctex-1-like	Family
IPR038586	Tctex-1-like_sf	Homologous_superfamily

Pfam: PF03645

UniProt features (8 total): region of interest 2, mutagenesis site 2, chain 1, compositionally biased region 1, modified residue 1, sequence variant 1

Structure

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q5JR98-F1	74.02	0.48

Human Protein Atlas

Protein class: Predicted intracellular proteins

Protein evidence: Evidence at protein level

Subcellular location (HPA, imaging): vesicles

Antibody reliability (HPA): IH enhanced · IF supported

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1)

Type	Positions
Phosphoserine	66

Mutagenesis-validated functional residues (2)

Position	Phenotype
90–93	partially reduces the binding to pp1cc.
93	decreased colocalization with ppp1cc by 27%.

Function

Pathways and Gene Ontology

Reactome pathways

0 curated (TAS) of 0; 0 disease pathways. Curated-first; evidence = TAS (manually curated) vs IEA (electronic inference).

MSigDB gene sets: 60 (showing top): GOCC_SECRETORY_GRANULE, GOCC_MICROTUBULE_ORGANIZING_CENTER, chr1p34, GOCC_CYTOPLASMIC_REGION, GOCC_SECRETORY_VESICLE, GOCC_MOTILE_CILIUM, MARSON_BOUND_BY_FOXP3_STIMULATED, MARSON_BOUND_BY_FOXP3_UNSTIMULATED, GOCC_CYTOPLASMIC_DYNEIN_COMPLEX, GOCC_DYNEIN_COMPLEX, GOCC_ACROSOMAL_VESICLE, GOCC_CILIUM, GOMF_PROTEIN_PHOSPHATASE_BINDING, GOMF_PHOSPHATASE_BINDING, GOMF_PROTEIN_PHOSPHATASE_1_BINDING

GO Biological Process (1): microtubule-based movement (GO:0007018)

GO Molecular Function (3): protein phosphatase 1 binding (GO:0008157), dynein intermediate chain binding (GO:0045505), protein binding (GO:0005515)

GO Cellular Component (9): acrosomal vesicle (GO:0001669), nucleus (GO:0005634), cytoplasm (GO:0005737), microtubule organizing center (GO:0005815), cytoplasmic dynein complex (GO:0005868), axoneme (GO:0005930), sperm flagellum (GO:0036126), cytoplasmic vesicle (GO:0031410), motile cilium (GO:0031514)

GO top-level categories

17 GO namespaces:

Category	Terms
cellular anatomical structure	3
microtubule-based process	1
protein phosphatase binding	1
protein binding	1
binding	1
secretory granule	1
intracellular membrane-bounded organelle	1
intracellular anatomical structure	1
microtubule cytoskeleton	1
dynein complex	1
cytoskeleton	1
microtubule	1
ciliary plasm	1
9+2 motile cilium	1
cytoplasm	1
intracellular vesicle	1
cilium	1

Experimentally-supported GO annotations

GO terms backed by direct experimental evidence (ECO experimental codes) — 5 of 13 annotations. The rest are phylogenetic / computational / electronic (IEA).

5 experimentally-supported GO terms:

GO term	NS	Evidence
acrosomal vesicle	CC	direct assay
axoneme	CC	direct assay
microtubule organizing center	CC	direct assay
sperm flagellum	CC	direct assay
protein phosphatase 1 binding	MF	direct assay

Protein interactions and networks

STRING

showing 15 of 1,006 interactions by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
DYNLT4	DYNLT1	P63172	878
DYNLT4	ENG	P17813	700
DYNLT4	TGFBR2	P37173	540
DYNLT4	DYNC1LI2	O43237	513
DYNLT4	DYNLT3	P51808	486
DYNLT4	DYNLRB2	Q8TF09	483
DYNLT4	DYNC2LI1	Q8TCX1	476
DYNLT4	DYNC1I1	O14576	469
DYNLT4	ESD	P10768	469
DYNLT4	DYNC1LI1	Q9Y6G9	468
DYNLT4	HIVEP3	Q5T1R4	453
DYNLT4	DYNLL2	Q96FJ2	442
DYNLT4	DYNLRB1	Q9NP97	416
DYNLT4	C1orf21	Q9H246	390
DYNLT4	DYNLT5	Q8N7M0	375

IntAct

Human interaction partners of DYNLT4 in IntAct, one row per partner (best MIscore; records = supporting IntAct interaction records).

6 partners by confidence:

Partner	Interaction type	MIscore	Records
MDFI	physical association	0.560	3
PPP1CC	physical association	0.510	5
PPP1CA	physical association	0.370	1
BAG3	association	0.350	1
NPR1	association	0.350	1
TRO	association	0.350	1

Disease & clinical

Genetic variants

Variant evidence for DYNLT4: 61 ClinVar records (0 pathogenic / likely pathogenic).

ClinVar

61 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	55
Likely benign	2
Benign	0

SpliceAI

Top 10 splice-impact sites by Δscore (adjacent positions with the same effect merged into one range; 14 predictions of 154):

Position(s)	Effect	Δscore	Sites
1:44807269	donor_gain	0.8600
1:44806680	acceptor_gain	0.7400
1:44806782–44806783	donor_loss	0.7400	4
1:44806783	donor_loss	0.7300
1:44806680	acceptor_gain	0.7100
1:44806681	acceptor_gain	0.6900	2
1:44806782	donor_loss	0.6800
1:44807329	donor_gain	0.6700
1:44806361	acceptor_gain	0.6400
1:44807246	donor_gain	0.6100

AlphaMissense

119 missense substitutions predicted likely pathogenic (of 1,364 scored), across 44 residues. Top 20 hotspot residues, ranked by the number of likely-pathogenic substitutions (of those reachable by a single-nucleotide change), then by mean score:

Residue	Likely-pathogenic substitutions	Mean am_pathogenicity	Max am_pathogenicity
D197	8	0.737	0.842
F210	7	0.862	0.972
W192	6	0.770	0.834
S188	5	0.855	0.927
K169	5	0.819	0.944
W118	5	0.812	0.845
D193	5	0.632	0.658
N206	4	0.828	0.877
G177	4	0.792	0.814
Y219	4	0.681	0.799
H216	4	0.661	0.774
G217	4	0.639	0.742
F93	3	0.820	0.820
S173	3	0.745	0.745
S92	3	0.744	0.744
Y168	3	0.734	0.824
C172	3	0.693	0.765
F61	3	0.656	0.656
L176	3	0.637	0.695
C153	3	0.634	0.673

HPA cancer prognostics

RNA cancer specificity: Cancer enhanced (Uterine Corpus Endometrial Carcinoma)

Disease associations

OMIM: gene MIM:611713 | disease phenotypes:

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (CPIC guideline: no)

CTD chemical–gene interactions

16 total (human), top 16 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Air Pollutants	decreases expression, increases abundance, increases expression	2
Smoke	increases abundance, increases expression	2
S-(1,2-dichlorovinyl)cysteine	affects cotreatment, increases expression	1
abrine	increases expression	1
Grape Seed Proanthocyanidins	affects cotreatment, increases expression	1
jinfukang	affects cotreatment, increases expression	1
Acetaminophen	increases expression	1
Arsenic	affects methylation	1
Benzo(a)pyrene	increases methylation	1
Catechin	affects cotreatment, increases expression	1
Cisplatin	affects cotreatment, increases expression	1
Lipopolysaccharides	affects cotreatment, increases expression	1
N-Nitrosopyrrolidine	increases expression	1
Tobacco Smoke Pollution	decreases expression	1
Valproic Acid	increases methylation	1
Particulate Matter	decreases expression, increases abundance	1

Clinical trials (associated diseases)

Via MONDO — disease-level, not drug-specific.

showing 60 of 210 trials:

NCT	Phase	Status	Title
NCT04586348	Phase 4	UNKNOWN	Prenatal Iodine Supplementation and Early Childhood Neurodevelopment
NCT04873115	Phase 4	UNKNOWN	Double-blind, Placebo-controlled, Randomized Clinical Trial Comparing the Efficacy and Safety of Sialanar Plus orAl rehabiLitation Against Placebo Plus Oral Rehabilitation for chIldren and Adolescents With seVere Sialorrhoea and Neurodisabilties,
NCT02559102	Phase 3	COMPLETED	Dexmedetomidine Sedation Versus General Anaesthesia for Inguinal Hernia Surgery in Infants
NCT02757079	Phase 3	COMPLETED	Study of the Efficacy and Safety of NPC-15 for Sleep Disorders of Children With Neurodevelopmental Disorders
NCT06915480	Phase 3	RECRUITING	Reducing Missed Appointments
NCT07377032	Phase 3	RECRUITING	TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders
NCT02909959	Phase 2	COMPLETED	Sulforaphane for the Treatment of Young Men With Autism Spectrum Disorder
NCT06081348	Phase 2	RECRUITING	Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders
NCT06352372	Phase 2	COMPLETED	Safety and Efficacy of tPBM for Epileptiform Activity in Autism
NCT00503191	Phase 1	COMPLETED	NeuroModulation Technique Treatment of Autism
NCT04475848	Phase 1	COMPLETED	A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of RO6953958 in Healthy Participants
NCT06300398	Phase 1	COMPLETED	IAMA-6 Oral Dose Study in Healthy Adults
NCT01783041	Phase 2/3	COMPLETED	Effect of Early L-Carnitine Supplementation on Neurodevelopmental Outcomes in Very Preterm Infants
NCT05767385	Phase 2/3	COMPLETED	Fetal Cerebrovascular Autoregulation in Congenital Heart Disease and Association With Neonatal Neurobehavior
NCT05675098	Early Phase 1	NOT_YET_RECRUITING	Central Nervous System Stimulants and Physical Function in Children With Cerebral Palsy
NCT00783783	Not specified	COMPLETED	CYP2D6 Pharmacogenetics in Risperidone-Treated Children
NCT01778504	Not specified	RECRUITING	Studying Childhood-onset Behavioral, Psychiatric, and Developmental Disorders
NCT01850784	Not specified	UNKNOWN	High Energy Formula Feeding in Infants With Congenital Heart Disease
NCT01922791	Not specified	COMPLETED	Nutrition and Pregnancy Intervention Study
NCT01942525	Not specified	UNKNOWN	Influence of Intrauterine Growth Restriction on Amplitude-integrated EEG in Preterm Infants
NCT02003170	Not specified	COMPLETED	Etiology and Early Diagnosis of Neurodevelopmental Disorders
NCT02118649	Not specified	COMPLETED	Enhancing Behavior and Brain Response to Visual Targets Using a Computer Game
NCT02557191	Not specified	TERMINATED	Biomarkers, Neurodevelopment and Preterm Infants
NCT02690675	Not specified	COMPLETED	Iron Supplement Effect on Child Development
NCT02694003	Not specified	COMPLETED	Better Nights, Better Days for Children With Neurodevelopment Disorders
NCT02792894	Not specified	COMPLETED	Family Networks (FaNs) for Children With Developmental Disorders and Delays
NCT02871674	Not specified	UNKNOWN	Good Night Project: Behavioural Sleep Interventions for Children With ADHD: A Randomised Controlled Trial
NCT02887157	Not specified	COMPLETED	Analyzing Retinal Microanatomy in ROP
NCT02898298	Not specified	COMPLETED	Positive Emotion Regulation Training in Children, Adolescents and Young Adults With and Without Developmental Disorder
NCT02912780	Not specified	UNKNOWN	Introduction of Microsystems in a Level 3 Neonatal Intensive Care Unit
NCT03023293	Not specified	COMPLETED	n-3 PUFAs, Irisin and Maternal Glucose Metabolism From Pregnancy to Postpartum
NCT03023644	Not specified	COMPLETED	Improving Neurodevelopmental Outcomes in Children With Congenital Heart Disease: An Intervention Study
NCT03032991	Not specified	UNKNOWN	Early Biomarkers of Neurodevelopment in Offspring of Diabetic Mothers
NCT03088189	Not specified	TERMINATED	Effect of Parental Peri-conceptional Vitamin B12 Supplementation on Infant Neurocognitive Development in Offspring
NCT03096028	Not specified	COMPLETED	Developmental Origins of Mental Health Disorders
NCT03148782	Not specified	COMPLETED	Brain Plasticity Underlying Acquisition of New Organizational Skills in Children-R61 Phase
NCT03172104	Not specified	COMPLETED	Neurobehavioural Development of Infants Born <30 Weeks Gestational Age Between Birth and Five Years of Age
NCT03222375	Not specified	RECRUITING	SQUED™ Series 28.1 Home-use and Treatment of Autowave Reverberator of Autism
NCT03229928	Not specified	COMPLETED	Clinical Testing of a Real-Time Behavior Measurement Tool: Measuring Outcomes for CHAnge
NCT03232489	Not specified	UNKNOWN	Study for the Evaluation of the Feasibility of Applying Advanced MRI Scanning in Pediatric Clinical Practice
NCT03381027	Not specified	COMPLETED	BABY SMART (Study of Massage Therapy, Sleep And neurodevelopMenT)
NCT03388294	Not specified	COMPLETED	Evaluation of a Novel Intervention for Infants At Risk for Neurodevelopmental Disorders
NCT03410810	Not specified	UNKNOWN	Childhood Outcomes of Preterm Brain Abnormalities
NCT03492060	Not specified	RECRUITING	Longitudinal Study of Neurogenetic Disorders
NCT03577756	Not specified	COMPLETED	Neurodevelopmental Assessment of Infants With Cystic Fibrosis
NCT03654248	Not specified	COMPLETED	Let’s Get Organized in Adult Psychiatric/habilitation Care
NCT03659279	Not specified	COMPLETED	Let’s Get Organized Feasibility Study
NCT03722615	Not specified	COMPLETED	Epidemiology of Congenital Cytomegalovirus in a High HIV Prevalence Setting, South Africa
NCT03770832	Not specified	ACTIVE_NOT_RECRUITING	Wearable Sensors and Video Recordings to Monitor Motor Development
NCT03830879	Not specified	RECRUITING	Shenzhen Birth Cohort Study
NCT03835689	Not specified	COMPLETED	Strongest FamiliesTM Neurodevelopmental
NCT03882788	Not specified	COMPLETED	The Effect of Anesthesia on Neurodevelopmental Outcome (NDO)
NCT03922087	Not specified	COMPLETED	No-worry Baby Project
NCT03977259	Not specified	ACTIVE_NOT_RECRUITING	Targeting Human Milk Fortification to Improve Preterm Infant Growth and Brain Development
NCT04043572	Not specified	UNKNOWN	The Biomarkers of Neurological Disease in Utero Study
NCT04096430	Not specified	RECRUITING	Evaluation of Effectiveness of Child-oriented Goal-setting in Paediatric Rehabilitation (the ENGAGE Approach)
NCT04108273	Not specified	COMPLETED	Brain Plasticity Underlying Acquisition of New Organizational Skills in Children
NCT04201509	Not specified	COMPLETED	Validity of Neurocognitive Assessment Methods in Childhood ADHD
NCT04233775	Not specified	UNKNOWN	Altered Cerebral Growth and Development in Infants With Congenital Heart Disease
NCT04313283	Not specified	COMPLETED	Translating Peer-to-Peer Support Into a Clinical Setting